Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 73, Issue 1, 2014, Pages 270-276

  Suwannalai, Parawee ^a,b   Britsemmer, Karin ^c   Knevel, Rachel ^a   Scherer, Hans Ulrich ^a   Levarht, E W Nivine ^a   Van Der Helm Van Mil, Annette H ^a   Van Schaardenburg, Dirkjan ^c   Huizinga, Tom W J ^a   Toes, René E M ^a   Trouw, L A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAHIDOL UNIVERSITY   (Thailand)

^c Reade   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CITRULLINATED PROTEIN ANTIBODY; FC RECEPTOR; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CELL ACTIVATION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; JOINT DESTRUCTION; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; YOUNG ADULT;

ANT-CCP; ARTHRITIS; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODY AFFINITY; ANTIGENS; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; COHORT STUDIES; COMPLEMENT SYSTEM PROTEINS; EPITOPES; FEMALE; FOLLOW-UP STUDIES; HUMANS; JOINTS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84889635694     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202615     Document Type: Article

References (39)

1. Harris ED Jr., Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990;322:1277-89. (Pubitemid 20152491)
2. Smolen JS, Aletaha D, Steiner G. Does damage cause inflammation? Revisiting the link between joint damage and inflammation. Ann Rheum Dis 2009;68:159-62.
3. Jansen LM, van Schaardenburg D, van der Horst-Bruinsma I, et al. The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol 2003;30:1691-5. (Pubitemid 36962444)
4. Kroot EJ, de Jong BA, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
5. Lindqvist E, Eberhardt K, Bendtzen K, et al. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005;64:196-201. (Pubitemid 40193611)
6. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50:709-15. (Pubitemid 38326168)
7. Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004;50:2072-81. (Pubitemid 38924384)
8. van der Kooij SM, le Cessie S, Goekoop-Ruiterman YP, et al. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis 2009;68:1153-8.
9. van der Linden MP, le Cessie S, Raza K, et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum 2010;62:3537-46.
10. van der Helm-van Mil AH, Wesoly JZ, Huizinga TW. Understanding the genetic contribution to rheumatoid arthritis. Curr Opin Rheumatol 2005;17:299-304. (Pubitemid 40616576)
11. Clavel C, Nogueira L, Laurent L, et al. Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum 2008;58:678-88. (Pubitemid 351364865)
12. Schuerwegh AJ, Ioan-Facsinay A, Dorjee AL, et al. Evidence for a functional role of IgE anticitrullinated protein antibodies in rheumatoid arthritis. Proc Natl Acad Sci USA 2010;107:2586-91.
13. Trouw LA, Haisma EM, Levarht EW, et al. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum 2009;60:1923-31.
14. Syversen SW, Gaarder PI, Goll GL, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008;67:212-17. (Pubitemid 351183310)
15. Ioan-Facsinay A, Willemze A, Robinson DB, et al. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum 2008;58:3000-8.
16. van der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A, et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 2010;69:1554-61.
17. Verpoort KN, Jol-van der Zijde CM, Papendrecht-van der Voort EA, et al. Isotype distribution of anti-cyclic citrullinated peptide antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum 2006;54:3799-808. (Pubitemid 44955880)
18. Scherer HU, van der Woude D, Ioan-Facsinay A, et al. Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. Arthritis Rheum 2010;62:1620-9.
19. Suwannalai P, Scherer HU, van der Woude D, et al. Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens. Ann Rheum Dis 2011;70:373-9.
20. Suwannalai P, van de Stadt LA, Radner H, et al. Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 2012;64:1323-8.
21. Cucnik S, Kveder T, Krizaj I, et al. High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis 2004;63:1478-82. (Pubitemid 39433954)
22. Villalta D, Romelli PB, Savina C, et al. Anti-dsDNA antibody avidity determination by a simple reliable ELISA method for SLE diagnosis and monitoring. Lupus 2003;12:31-6. (Pubitemid 36172660)
23. Zhang Y, Gao Y, Li M, et al. Avidity of thyroglobulin antibody in sera from patients with Hashimoto's thyroiditis with different thyroid functional status. Clin Exp Immunol 2010;161:65-70.
24. de Rooy DP, van der Linden MP, Knevel R, et al. Predicting arthritis outcomes - what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford) 2011;50:93-100.
25. van der Linden MP, Feitsma AL, le CS, et al. Association of a single-nucleotide polymorphism in CD40 with the rate of joint destruction in rheumatoid arthritis. Arthritis Rheum 2009;60:2242-7.
26. Willemze A, Trouw LA, Toes RE, et al. The influence of ACPA status and characteristics on the course of RA. Nat Rev Rheumatol 2012;8:144-52.
27. van der Helm-van Mil AH, Knevel R, van der HD, et al. How to avoid phenotypic misclassification in using joint destruction as an outcome measure for rheumatoid arthritis?. Rheumatology (Oxford) 2010;49:1429-35.
28. Scherer HU, van der Woude D, Willemze A, et al. Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis. Ann Rheum Dis 2011;70:1461-4.
29. Ursum J, Bos WH, van DN, et al. Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study. Arthritis Res Ther 2010;12:R8
30. Snir O, Widhe M, Hermansson M, et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum 2010;62:44-52.
31. Bang H, Egerer K, Gauliard A, et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007;56:2503-11. (Pubitemid 47237269)
32. Vossenaar ER, Smeets TJ, Kraan MC, et al. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 2004;50:3485-94. (Pubitemid 39488673)
33. Adams GP, Schier R, McCall AM, et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 2001;61:4750-5. (Pubitemid 32691886)
34. Rudnick SI, Lou J, Shaller CC, et al. Influence of affinity and antigen internalization on the uptake and penetration of anti-HER2 antibodies in solid tumors. Cancer Res 2011;71:2250-9.
35. Germuth FG Jr., A comparative histologic and immunologic study in rabbits of induced hypersensitivity of the serum sickness type. J Exp Med 1953;97:257-82.
36. Delgado MF, Coviello S, Monsalvo AC, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009;15:34-41.
37. Polack FP, Hoffman SJ, Crujeiras G, et al. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat Med 2003;9:1209-13. (Pubitemid 37173707)
38. Daha NA, Banda NK, Roos A, et al. Complement activation by (auto-) antibodies. Mol Immunol 2011;48:1656-65.
39. Kaufman EN, Jain RK. Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays. Cancer Res 1992;52:4157-67.